Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A composition comprising a compound of formula (I):



(I)

wherein

L is a direct bond, or an optionally C_{1-4}alkyl substituted radical selected from the group consisting of C_{1-4}alkylene or C_{3-4}alkenylene wherein NR^1R^2 is attached to an sp^3 hybridized carbon, C_{3-4}alkynylene wherein NR^1R^2 is attached to an sp^3 hybridized carbon, C_{2-4}alkylidene wherein NR^1R^2 is attached to an sp^3 hybridized carbon, aryloxy wherein NR^1R^2 is not attached to the oxygen, arylthio wherein NR^1R^2 is not attached to the sulfur, C_{2-4}alkoxy wherein NR^1R^2 is not attached to the oxygen or a carbon attached to the oxygen, C_{2-4}alkylthio wherein NR^1R^2 is not attached to the sulfur or a carbon attached to the sulfur, and $-C_{2-3}$alkyl-X-C_{1-2}alkyl- wherein X is O, S or NH and wherein NR^1R^2 is not attached to a carbon attached to X;

p is 0, 1 or 2;

q is 1 or 2; provided that $2 \leq p+q \leq 4$;

~~R^1 is a substituent independently selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{3-6} alkenyl, C_{3-9} carbocyclyl, 3-12 membered heterocyclyl, phenyl, (5-9-membered heterocyclyl)C_{1-6} alkylene, and (phenyl)C_{1-6} alkylene;~~

~~R^2 is a substituent independently selected from the group consisting of C_{1-6} alkyl, C_{3-6} alkenyl, C_{3-9} membered carbocyclyl, 3-12~~

~~membered heterocyclyl, phenyl, (5-9-membered heterocyclyl)C_{1-6} alkylene, and (phenyl)C_{1-6} alkylene;~~

~~or~~ R^1 and R^2 taken together with the nitrogen to which they are attached form piperidinyl or pyrrolidinyl~~a saturated 3-13 membered N-linked heterocyclyl, wherein, in addition to the N-linking nitrogen, the 3-13 membered heterocyclyl may optionally contain between 1 and 3 additional heteroatoms independently selected from O, S, and NH~~;

wherein R^1 and R^2 are optionally and independently substituted with 1-3 substituents selected from the group consisting of *tert*-butyloxycarbonyl, hydroxy, halo, nitro, amino, cyano, carboxamide, C_{1-6} alkyl, C_{1-6} acyl, 5-9-membered heterocyclyl, -N(C_{1-6} alkyl)(5-9 membered heterocyclyl), -NH(5-9 membered heterocyclyl), -O(5-9 membered heterocyclyl), (5-9 membered heterocyclyl)C_{1-3} alkylene, C_{1-2}-hydroxyalkylene, C_{1-6} alkoxy, (C_{3-6} cycloalkyl)-O-, phenyl, (phenyl)C_{1-3} alkylene, and (phenyl)C_{1-3} alkylene-O-; and wherein each of the preceding substituents of R^1 and R^2 may optionally have between 1 and 3 substituents independently selected from the group consisting of trifluoromethyl, halo, nitro, cyano, hydroxy, and C_{1-3} alkyl;

one of R^3, R^4 and R^5 is G and the other two independently are hydrogen, fluoro, chloro, bromo, nitro, trifluoromethyl, methyl, or C_{1-3} alkoxy ;

G is L^2Q;

L^2 is unbranched -$(CH_2)_n$- wherein n is an integer from 1 to 7;

Q is ~~NR^8R^9 wherein R^8 is independently selected from hydrogen, C_{1-6} alkyl, C_{3-6} alkenyl, C_{3-9} carbocyclyl, 3-12 membered heterocyclyl, phenyl, (5-9-membered heterocyclyl)C_{1-6} alkylene, and (phenyl)C_{1-6} alkylene; and R^9 is independently selected from C_{1-6} alkyl, C_{3-6} alkenyl, 3-9 membered carbocyclyl, 3-13 membered heterocyclyl, phenyl, (5-9-membered heterocyclyl)C_{1-6} alkylene, and (phenyl)C_{1-6} alkylene; or Q is a saturated 3-15 membered~~ a N-linked heterocyclyl which is piperidinyl or pyrrolidinyl~~, wherein,~~

~~in addition to the N-linking nitrogen, the 3-15 membered heterocyclyl may optionally contain between 1 and 4 additional heteroatoms independently selected from O, S, and NH~~;

wherein Q is optionally substituted with 1-3 substituents selected (in addition to the preceding paragraph) from the group consisting of *tert*-butyloxycarbonyl, hydroxy, halo, nitro, amino, cyano, carboxamide, C_{1-6} alkyl, C_{1-6} acyl, 5-9-membered heterocyclyl, -N(C_{1-6} alkyl)(5-9 membered heterocyclyl), -NH(5-9 membered heterocyclyl), -O(5-9 membered heterocyclyl), (5-9 membered heterocyclyl)C_{1-3} alkylene, C_{1-2}-hydroxyalkylene, C_{1-6} alkoxy, (C_{3-6} cycloalkyl)-O-, phenyl, (phenyl)C_{1-3} alkylene, and (phenyl)C_{1-3} alkylene-O-; and where said substituent groups of Q may optionally have between 1 and 3 substituents independently selected from trifluoromethyl, halo, nitro, cyano, hydroxy, and C_{1-3} alkyl;

R^a are independently C_{1-3} alkyl, triflouromethyl;

m is 0, 1, 2 or 3; and

wherein each of the above alkyl, alkylene, alkenyl, heterocyclyl, cycloalkyl, carbocyclyl, and aryl groups may each be independently and optionally substituted with between 1 and 3 substituents independently selected from methoxy, halo, amino, nitro, hydroxy, and C_{1-3} alkyl;

or a pharmaceutically acceptable salt, ester, tautomer, solvate or amide thereof.

2. (canceled)

3. (canceled)

4. (canceled)

5. (canceled)

6. (canceled)

7. (currently amended) A compound of claim 41, wherein NR^1R^2 taken together ~~form a substituent selected from the group consisting of morpholinyl and piperidinyl, wherein said substituent~~ is optionally substituted with between 1 and 3 substituents selected from hydroxy, halo, carboxamide, C_{1-6} alkyl, C_{1-6} acyl, 5-9 membered heterocyclyl, -N(C_{1-6} alkyl)(5-9 membered heterocyclyl), -NH(5-9 membered heterocyclyl), -O(5-9 membered heterocyclyl), (5-9 membered heterocyclyl)C_{1-3} alkylene, C_{1-2}-hydroxyalkylene, C_{1-6} alkoxy, (C_{3-6} cycloalkyl)-O-, phenyl, (phenyl)C_{1-3} alkylene, and (phenyl)C_{1-3} alkylene-O- where each of above heterocyclyl, phenyl, and alkyl groups may be optionally substituted with from 1 to 3 substituents independently selected from trifluoromethyl, halo, nitro, cyano, hydroxy, and C_{1-3} alkyl.

8. (currently amended) A compound of claim ~~3~~1, wherein NR^1R^2 taken together ~~the saturated N-linked nitrogen-containing heterocyclyl~~ is substituted with a substituent selected from the group consisting of pyridyl, pyrimidyl, furyl, thiofuryl, imidazolyl, (imidazolyl)C_{1-6} alkylene, oxazolyl, thiazolyl, 2,3-dihydro-indolyl, benzimidazolyl, 2-oxobenzimidazolyl, (tetrazolyl)C_{1-6} alkylene, tetrazolyl, (triazolyl)C_{1-6} alkylene, triazolyl, (pyrrolyl)C_{1-6} alkylene, pyrrolidinyl, and pyrrolyl.

9. (canceled)

10. (canceled)

11. (canceled)

12. (canceled)

13. (canceled)

14. (original) A compound of claim 1, wherein one of R^3 and R^4 is G.

15. (currently amended) A compound of claim ~~1~~14, wherein R^4 is G.

16. (original) A compound of claim 14, wherein R^3 is G.

17. (original) A compound of claim 1, wherein q is 2 and p is 1.

18. (original) A compound of claim 1, wherein q is 1 and p is 1.

19. (original) A compound of claim 1, wherein q is 2 and p is 2.

20. (original) A compound of claim 1, wherein L is $-CH_2-$.

21. (original) A compound of claim 1, wherein L is a direct bond.

22. (original) A compound of claim 1, wherein L is $-CH_2CH_2-$.

23. (original) A compound of claim 1, wherein L^2 is $-CH_2-$

24. (canceled)

25. (canceled)

26. canceled)

27. (canceled)

28. (canceled)

29. (currently amended) A compound of claim ~~2~~51, wherein ~~Q is morpholinyl, pyridyl, or piperidinyl, and wherein~~ Q is optionally substituted with between 1 and 3 substituents selected from hydroxy,

halo, carboxamide, C_{1-6} alkyl, C_{1-6} acyl, 5-9 membered or 6-9 membered heterocyclyl, -N(C_{1-6} alkyl)(5-9 membered or 6-9 membered heterocyclyl), -NH(5-9 membered or 6-9 membered heterocyclyl), -O(5-9 or 6-9 membered heterocyclyl), (5-9 membered or 6-9 membered heterocyclyl)C_{1-3} alkylene, C_{1-2}-hydroxyalkylene, C_{1-6} alkoxy, (C_{3-6} cycloalkyl)-O-, phenyl, (phenyl)C_{1-3} alkylene, and (phenyl)C_{1-3} alkylene-O- where each of above heterocyclyl, phenyl, and alkyl groups may be optionally substituted with from 1 to 3 substituents independently selected from trifluoromethyl, halo, nitro, cyano, hydroxy, and C_{1-3} alkyl.

30. (original) A compound of claim 29, wherein Q is substituted with a substituent comprising a 5-9 membered heterocyclyl group selected from: pyridyl, pyrimidyl, furyl, thiofuryl, imidazolyl, (imidazolyl)C_{1-6} alkylene, oxazolyl, thiazolyl, 2,3-dihydro-indolyl, benzimidazolyl, 2-oxobenzimidazolyl, (tetrazolyl)C_{1-6} alkylene, tetrazolyl, (triazolyl)C_{1-6} alkylene, triazolyl, (pyrrolyl)C_{1-6} alkylene, pyrrolidinyl, and pyrrolyl.

31. (canceled)

32 (canceled)

33. (canceled)

34. (canceled)

35. (canceled)

36. (canceled)

37. (canceled)

38. (canceled)

39. (canceled)

40. (canceled)

41. (canceled)

42. (currently amended) A compound of claim 1, wherein:

R^1 and R^2 ~~are independently selected from C_2 alkyl, or~~ taken together with the nitrogen to which they are attached, ~~they~~ form piperidinyl or pyrrolidinyl~~a non-aromatic 5-6 membered heterocyclyl optionally including an additional heteroatom independently selected from O, S, and NH~~;

one of R^3, R^4, and R^5 is G and the two remaining are H;

G is L^2Q;

L^2 is methylene;

Q is ~~NR^8R^9 wherein R^8 is independently selected from hydrogen, C_{1-2} alkyl, C_3 alkenyl, C_{5-9} carbocyclyl, 3-12 membered heterocyclyl, phenyl, (5-9-membered heterocyclyl)C_{1-6} alkylene, and (phenyl)C_{1-6} alkylene; and R^9 is independently selected from C_{1-2} alkyl, C_3 alkenyl, C_{5-9} carbocyclyl, 3-12 membered heterocyclyl, phenyl, (6-9-membered heterocyclyl)C_{1-6} alkylene, and (phenyl)C_{1-6} alkylene; or Q is a saturated 3-15 membered~~ a N-linked heterocyclyl which is piperidinyl or pyrrolidinyl~~, wherein, in addition to the N-linking nitrogen, the 3-15 membered heterocyclyl may optionally contain between 1 and 4 additional heteroatoms selected from O, S, and NH~~;

wherein each of the above alkyl, alkylene, alkenyl, alkenylene, heterocyclyl, and carbocyclyl groups may each be independently and optionally substituted with between 1 and 3 substituents selected from methoxy, halo, amino, nitro, hydroxyl, and C_{1-3} alkyl;

wherein substituents of Q can be further selected from *tert*-butyloxycarbonyl, hydroxy, halo, nitro, amino, cyano,

carboxamide, 5-9-membered heterocyclyl, -NH(6-membered heterocyclyl), -O(6-membered heterocyclyl), C_2-hydroxyalkylene, phenyl, benzyl and, where each of above heterocyclyl, phenyl, and alkyl substituent groups of Q may be optionally substituted with trifluoromethyl;

or a pharmaceutically acceptable salt, ester, tautomer, solvate or amide thereof.

43. (canceled)

44. (currently amended) A compound of claim 1, wherein ~~(a) NR^1R^2 taken together form piperidinyl or pyrrolidinyl, (b)~~ n is 1, ~~(c)~~ p is 1 and q is 2~~, and (d) Q is selected from morpholinyl and piperidinyl~~.

45. (currently amended) A compound of claim 1, wherein ~~(a) NR^1R^2 taken together form piperidinyl or pyrrolidinyl, (b)~~ n is 1, ~~(c)~~ p is ~~1~~ 2 and q is 2~~, and (d) Q is selected from morpholinyl and piperidinyl~~.

46. (currently amended) A compound of claim 44~~1~~, wherein Q is piperidinyl or substituted piperidinyl.

47. (canceled)

48. (original) A compound of claim 1 wherein R^a is hydrogen.

49. (currently amended) A compound of claim 1 selected from the group consisting of

~~4-{2-(4-Piperidin-1-ylmethyl-piperidin-1-yl)-benzyl}-morpholine;~~

~~Cyclohexyl-{1-(4-pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-amine;~~

~~1-{1-(4-Pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-azacyclotridecane;~~

~~Diethyl-{1-(4-pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-amine;~~

Dimethyl-{1-(4-pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-amine;

1-Methyl-4-{1-(4-pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-piperazine;

1-{1-(4-Pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-piperidin-4-ol;

4-{1-(4-Pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-thiomorpholine;

1-{1-(4-Pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-piperidine;

4-{1-(4-Pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-morpholine;

4-{3-(4-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-thiomorpholine;

4-{3-(4-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-morpholine;

4-Pyrrolidin-1-ylmethyl-1-(3-pyrrolidin-1-ylmethyl-phenyl)-piperidine;

1-{3-(4-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-piperidine;

1-{4-(4-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-azacyclotridecane;

Cyclohexyl-{4-(4-pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-amine;

1-{4-(4-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-piperidin-4-ol;

1-Methyl-4-{4-(4-pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-piperazine;

4-{4-(4-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-thiomorpholine;

4-{4-(4-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-morpholine;

Dimethyl-{4-(4-pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-amine;

4-{2-(4-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-morpholine;

4-{1-(4-Piperidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-morpholine;

1-{4-(4-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-piperidine;

Cyclohexyl-{1-(4-morpholin-4-ylmethyl-phenyl)-piperidin-4-yl}-amine;

Cyclohexyl-methyl-{1-(4-morpholin-4-ylmethyl-phenyl)-piperidin-4-yl}-amine;

4-{4-{4-(4-Methyl-piperazin-1-yl)-piperidin-1-yl}-benzyl}-morpholine;

Ethyl-methyl-{1-(4-morpholin-4-ylmethyl-phenyl)-piperidin-4-yl}-amine;

4-{1-(4-Morpholin-4-ylmethyl-phenyl)-piperidin-4-yl}-morpholine;

4-{4-(4-Pyrrolidin-1-yl-piperidin-1-yl)-benzyl}-morpholine;

1'-(4-Morpholin-4-ylmethyl-phenyl)-{1,4'}bipiperidinyl;

1'-(4-Piperidin-1-ylmethyl-phenyl)-{1,4'}bipiperidinyl;

(4-{1,4'}Bipiperidinyl-1'-yl-benzyl)-pyridin-2-yl-amine;

Phenyl-{1-(4-pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-amine;

~~Pyridin-2-yl-{1-(4-pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-amine;~~

1-{1-(4-Piperidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-piperidine;

4-Pyrrolidin-1-ylmethyl-1-(4-pyrrolidin-1-ylmethyl-phenyl)-piperidine;

~~(4-Fluoro-phenyl)-{4-(4-pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-amine;~~

~~4-{2-{1-(4-Piperidin-1-ylmethyl-phenyl)-pyrrolidin-3-yl}-ethyl}-morpholine;~~

~~Diethyl-{2-{1-(4-piperidin-1-ylmethyl-phenyl)-pyrrolidin-3-yl}-ethyl}-amine;~~

~~Methyl-phenethyl-{2-{1-(4-piperidin-1-ylmethyl-phenyl)-pyrrolidin-3-yl}-ethyl}-amine;~~

1-[4-(4-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-3-trifluoromethyl-benzyl]-piperidine;

1-(2-Nitro-4-pyrrolidin-1-ylmethyl-phenyl)-4-pyrrolidin-1-ylmethyl-piperidine;

~~4-[3-Nitro-4-(4-pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl]-morpholine;~~

1-[3-Nitro-4-(4-pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl]-piperidin-4-ol;

1-[4-(4-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-2-trifluoromethyl-benzyl]-piperidine;

~~1-Isopropyl-4-[3-methyl-4-(4-pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl]-piperazine;~~

1-(2-Methyl-4-pyrrolidin-1-ylmethyl-phenyl)-4-pyrrolidin-1-ylmethyl-pyrrolidine;

1-[3-Methyl-4-(4-pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl]-pyrrolidine;

1-{1-[4-(4-Pyrrolidin-1-yl-piperidin-1-ylmethyl)-2-trifluoromethyl-phenyl]-piperidin-4-ylmethyl}-pyrrolidine;

1-(1-{3-Trifluoromethyl-4-[4-(4-trifluoromethyl-phenyl)-piperidin-1-ylmethyl]-phenyl}-piperidin-4-ylmethyl)-pyrrolidine;

1-{1-[2-Fluoro-4-(4-phenyl-piperidin-1-ylmethyl)-phenyl]-piperidin-4-ylmethyl}-pyrrolidine;

~~[3-Fluoro-4-(4-pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl]-dimethyl-amine;~~

1-[3-Fluoro-4-(4-pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl]-piperidine;

and

~~13-[4-(4-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-2-trifluoromethyl-benzyl]-1,4,7,10-tetraoxa-13-aza-cyclopentadecane ditrifluoromethanesulfonate; and~~

{1-[4-(4-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-3-trifluoromethyl-benzyl]-piperidin-4-yl}-methanol.

50. (canceled)

51. (canceled)

52. (canceled)

53. (canceled)

54. (original) A pharmaceutical composition, comprising a compound of claim 1 and a pharmaceutically-acceptable excipient.

55. (canceled)

56. (canceled)

57. (canceled)

58. (canceled)

59. (canceled)

60. (canceled)

61. (canceled)

62. (canceled)

63. (original) A method for treating one or more disorders or conditions selected from the group consisting of sleep/wake disorders, narcolepsy, and arousal/vigilance disorders, comprising administering to a subject a therapeutically effective amount of a compound of claim 1.

64. (original) A method for treating attention deficit hyperactivity disorders (ADHD), comprising administering to a subject a therapeutically effective amount of a compound of claim 1.

65. (canceled)

66. (original) A method for treating or preventing upper airway allergic response, nasal congestion, or allergic rhinitis, comprising administering to a subject a therapeutically effective amount of a compound of claim 1.

67. (canceled)

68. (canceled)